Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.50 |
| ▸ | NPY4R | P50391 | 15/20 | 0.47 |
| ▸ | NPY1R | P25929 | 9/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.47 |
| ▸ | NPY2R | P49146 | 5/20 | 0.47 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30202495 | 1.00 | NOD1 (0.50) | NOD1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL1711608 | 1.00 | NOD1 (0.50) | NOD1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL23286096 | 1.00 | NOD1 (0.50) | NOD1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL23286085 | 0.97 | NOD1 (0.48) | NOD1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL5598692 | 0.97 | NOD1 (0.52) | NOD1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29697052 | 0.97 | NOD1 (0.52) | NOD1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL2490761 | 0.97 | NOD1 (0.52) | NOD1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31454130 | 0.97 | NOD1 (0.52) | NOD1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29787128 | 0.97 | NOD1 (0.52) | NOD1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL4587351 | 0.96 | NOD1 (0.51) | NOD1NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11419944-B2 | Non-linear self-immolative linkers and conjugates thereof | BYONDIS B.V. (NL) | 2022-08-23 | — | — | US | disclosed |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2021-07-06 | — | — | US | disclosed |
| US-20200297859-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | BYONDIS B.V. (NL) | 2020-09-24 | — | — | US | disclosed |
| EP-3525826-B1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | BYONDIS BV (NL) | 2020-07-22 | — | — | EP | disclosed |
| EP-3108886-B1 | CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | SYNTARGA BV (NL) | 2020-06-17 | — | — | EP | disclosed |
| EP-3525826-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | Synthon Biopharmaceuticals B.V. (NL) | 2019-08-21 | — | — | EP | disclosed |
| EP-1909846-B1 | TRIAZOLE-CONTAINING RELEASABLE LINKERS, CONJUGATES COMPRISING THE SAME AND PROCESSES FOR THEIR PREPARATION | SYNTARGA BV (NL) | 2018-12-26 | — | — | EP | disclosed |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-31 | — | — | US | disclosed |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-17 | — | — | US | disclosed |
| WO-2018069375-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2018-04-19 | — | — | WO | disclosed |
| US-20110065767-A1 | Substituted CC-1065 Analogs and Their Conjugates | SYNTARGA B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| WO-2010062171-A2 | NOVEL CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2010-06-03 | — | — | WO | disclosed |
| EP-2173739-A1 | SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES | Syntarga B.V. (NL) | 2010-04-14 | — | — | EP | disclosed |
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) (DE) | 2009-12-24 | — | — | US | disclosed |
| WO-2009017394-A1 | SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2009-02-05 | — | — | WO | disclosed |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | BYONDIS B.V. (NL) | 2008-12-18 | — | — | US | disclosed |
| EP-1994000-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | Syntarga B.V. (NL) | 2008-11-26 | — | — | EP | disclosed |
| EP-1909846-A2 | TRIAZOLE-CONTAINING RELEASABLE LINKERS, CONJUGATES THEREOF, AND METHODS OF PREPARATION | Syntarga B.V. (NL) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007089149-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007018431-A2 | TRIAZOLE-CONTAINING RELEASABLE LINKERS AND CONJUGATES COMPRISING THE SAME | SYNTARGA B.V. (NL) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | PCNA, DCK, BAD | NOD1 3209/4885NPY4R 4879/4885NPY1R 4827/4885 |
| US-20200297859-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | DLST, ADSL, LANCL1 | NOD1 1332/4885NPY4R 4099/4885NPY1R 4084/4885 |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | PAICS, CD44, TRIM33 | NOD1 721/4885NPY4R 4278/4885NPY1R 3919/4885 |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | NOD1 3666/4885NPY4R 4799/4885NPY1R 4584/4885 |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | PCNA, DCLRE1A, CDC5L | NOD1 3770/4885NPY4R 4742/4885NPY1R 4410/4885 |
| US-20110065767-A1 | Substituted CC-1065 Analogs and Their Conjugates | PCNA, TOP1, TOP2B | NOD1 4345/4885NPY4R 4794/4885NPY1R 4687/4885 |
| US-11419944-B2 | Non-linear self-immolative linkers and conjugates thereof | DLST, ADSL, LANCL1 | NOD1 1332/4885NPY4R 4099/4885NPY1R 4084/4885 |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | NOD1 3666/4885NPY4R 4799/4885NPY1R 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.